Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ocrevus on Microglial Activation in Multiple Sclerosis (PET-MRI 18F-DPA714)
2017-004158-40Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ocrelizumab in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (2 cohorts), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary: Percent change in 18F-DPA714 positive voxels in total white matter at 24 months. Started Jul 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2017-004158-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004158-40.